Pharming (Euronext: PHARM / Nasdaq: PHAR) announced its 2026 Annual General Meeting of Shareholders will be held on Thursday, May 28, 2026 at 14:00 CET in Oegstgeest, the Netherlands, and via live webcast.
Agenda items include appointing KPMG N.V. as external auditor for 2026–2028, proposed amendments to the Board remuneration policy for Non‑Executive Directors, and renewal of authorizations to issue and repurchase shares. Meeting documents and proxy materials are available on the company website under Investors/Shareholder Meetings.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement outlines Pharming’s 2026 AGM, scheduled for May 28, 2026 at 14:00 CET, with propos...
Analysis
This announcement outlines Pharming’s 2026 AGM, scheduled for May 28, 2026 at 14:00 CET, with proposals covering auditor appointment for 2026–2028, Board remuneration changes, and renewed authorizations to issue and repurchase shares. These items frame future governance and capital decisions. Investors may focus on how any new authorizations are structured, the scope of potential share issuance or buybacks, and future disclosures following AGM approval outcomes.
Key Figures
AGM date:May 28, 2026AGM time:14:00 CETAuditor term:2026–2028+3 more
6 metrics
AGM dateMay 28, 20262026 Annual General Meeting of Shareholders
AGM time14:00 CETScheduled starting time of AGM
Auditor term2026–2028Financial years for proposed KPMG N.V. appointment
AGM year2026Year of the Annual General Meeting of Shareholders
Venue street number1Willem Einthovenstraat 1, Corpus Congress Centre address
Postal code2342 BHPostal code for Oegstgeest venue location
Key Terms
proxy, external auditor, remuneration policy, non-executive directors, +3 more
7 terms
proxyregulatory
"The Notice to Convene, Explanatory Notes, Proxy and other meeting documents"
A proxy is the authorization a shareholder gives to another person or document to cast votes on their behalf at a company meeting. Think of it like handing someone your voting ticket so they can represent your choices on board elections, executive pay, mergers and other big decisions; it matters because proxies determine who controls the company and which proposals pass, directly affecting share value and investor returns.
external auditorregulatory
"includes the proposal to appoint KPMG N.V. as the Company’s external auditor"
An external auditor is an independent, third-party professional who reviews a company’s financial records and reports to confirm they are accurate and follow the rules. Like a home inspector checking a house before you buy, an external auditor gives investors assurance that the numbers reflect reality, which affects trust, the perceived risk of the company, and therefore investment decisions and value.
remuneration policyfinancial
"proposals to amend the Remuneration policy for the Board of Directors"
A remuneration policy is a company’s written guide on how it pays executives and senior managers, covering salary, bonuses, stock awards and other benefits. It matters to investors because it shows how pay is linked to long-term performance and risk—like a recipe that determines whether incentives encourage sustainable growth or reward short-term gains—affecting governance, shareholder returns and potential conflicts of interest.
non-executive directorsregulatory
"regarding the fees to be paid to the Non-Executive Directors"
Non-executive directors are board members who do not work for the company day-to-day but oversee management, like an independent referee watching a game rather than playing. They matter to investors because they provide impartial checks on executive decisions, help shape long-term strategy, monitor risks and financial reporting, and guard shareholder interests—contributing to better governance and reducing the chance of mismanagement or conflicts of interest.
issue sharesfinancial
"includes the renewal of the authorizations for the Board of Directors to issue shares"
When a company issues shares it creates and sells new pieces of ownership in the business to raise money. For investors this matters because it can bring cash for growth, debt repayment or acquisitions, but also reduces each existing shareholder’s percentage ownership and can lower earnings per share—like slicing a pie into more pieces so each past slice becomes smaller. Tracking issuances helps assess dilution and capital strategy.
rights to acquire sharesfinancial
"issue shares (including rights to acquire shares), and to repurchase shares"
Rights to acquire shares are contractual entitlements that let a holder buy a company’s stock at a set price and within a set time, similar to a coupon or ticket that can be redeemed for ownership. They matter to investors because exercising them can preserve or increase one’s ownership stake, provide a chance to buy stock at a known price before public sale, and affect existing shareholders by changing how much of the company each person owns.
repurchase sharesfinancial
"authorizations for the Board of Directors to issue shares ... and to repurchase shares"
A company buying back its own outstanding stock from the market or directly from shareholders, reducing the number of shares available to the public. For investors this matters because it can boost per-share metrics and share price by concentrating ownership and signaling management’s confidence, but it also uses cash that could be spent elsewhere—think of a store redeeming gift cards to reduce outstanding coupons and make the remaining ones effectively more valuable.
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held on Thursday May 28, 2026, at 14:00 CET. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings.
The agenda of the AGM includes the proposal to appoint KPMG N.V. as the Company’s external auditor for the financial years 2026 through 2028 and the proposals to amend the Remuneration policy for the Board of Directors regarding the fees to be paid to the Non-Executive Directors.
The agenda of the AGM also includes the renewal of the authorizations for the Board of Directors to issue shares (including rights to acquire shares), and to repurchase shares.
The AGM will be held at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands, and will be webcast live.
About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact: Investor Relations Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com
When is Pharming's 2026 Annual General Meeting (PHARM) scheduled?
The AGM is scheduled for Thursday, May 28, 2026 at 14:00 CET. According to Pharming, the meeting will be held at the Corpus Congress Centre in Oegstgeest and will also be available via live webcast for remote shareholders.
Where will Pharming (PHARM) hold the 2026 AGM and is there a webcast?
Pharming will hold the AGM at the Corpus Congress Centre, Oegstgeest, and it will be webcast live. According to Pharming, meeting documents and access details are published under Investors/Shareholder Meetings on the company website.
What auditor appointment is on the PHARM AGM agenda for 2026–2028?
The AGM proposes appointing KPMG N.V. as external auditor for financial years 2026 through 2028. According to Pharming, shareholders will vote on the auditor appointment as part of the formal AGM agenda.
What board remuneration changes are proposed at the Pharming (PHARM) AGM?
The proposal seeks to amend the Remuneration policy regarding fees for Non‑Executive Directors. According to Pharming, shareholders will consider updated fee arrangements for the Board of Directors during the AGM vote.
What share issuance and repurchase authorizations are on the PHARM AGM agenda?
The AGM agenda includes renewal of authorizations for the Board to issue shares and to repurchase shares. According to Pharming, these renewals are standard governance items requiring shareholder approval to enable future capital or buyback actions.
Where can PHARM shareholders find the Notice to Convene and proxy documents for the 2026 AGM?
Shareholders can find the Notice to Convene, Explanatory Notes, proxy and meeting documents on Pharming's investor website under Investors/Shareholder Meetings. According to Pharming, all relevant materials are published ahead of the May 28, 2026 AGM.
